Abstract
New inodilators that possess both positive inotropic and vasodilator actions have many favorable effects in patients with congestive heart failure, even in those with refractory heart failure. These effects are expected to prevent myocardial injury, improve peripheral circulation, depress the excessive endogenous neurohumoral activation, and, finally, improve the quality of life, and increase lifespan. However, experience with new inodilators has only begun. Several questions remain to be answered before these drugs can be widely used with safety, including whether life-threatening adverse effects appear, mortality rate is lessened, and drug tolerance occurs. The therapeutic level of the dose and the relation between the effectiveness of the drug and the degree of the severity of heart failure should also be established. Therefore, long-term, randomized, double-blind, placebo-controlled clinical trials will be necessary before the new inodilators can take the place of digitalis and thus become the mainstay of the therapy of congestive heart failure.
References
Feb 1, 1977·Circulation·H S LoebR M Gunner
Jan 1, 1978·Annual Review of Pharmacology and Toxicology·L I GoldbergJ D Kohli
Dec 21, 1978·The New England Journal of Medicine·A M Katz
Apr 1, 1977·The American Journal of Cardiology·T A GillespieR Roberts
Jul 1, 1976·The American Journal of Cardiology·S L MeyerJ T Willerson
Dec 1, 1976·The American Journal of Cardiology·M V CohenE S Kirk
May 1, 1976·Circulation·J T WillersonG H Templeton
Jul 22, 1985·The American Journal of Cardiology·D ManciniE Sonnenblick
Jan 11, 1985·The American Journal of Cardiology·G S Francis
Aug 14, 1987·The American Journal of Cardiology·E InstalléJ Tremouroux
Aug 14, 1987·The American Journal of Cardiology·K KhalifeJ M Gilgenkrantz
Jan 30, 1986·The New England Journal of Medicine·J E MullerUNKNOWN MILIS Study Group
Jul 22, 1985·The American Journal of Cardiology·S H TaylorB Silke
Sep 1, 1974·The Journal of Clinical Investigation·S F VatnerE Braunwald
Apr 1, 1970·Annals of Internal Medicine·S E EpsteinM Entman
Feb 1, 1973·Circulation·J Morrison, T Killip
Nov 1, 1973·The New England Journal of Medicine·T W Smith, E Haber
Aug 1, 1974·The American Journal of Physiology·S DavidsonE Braunwald
Aug 1, 1972·Circulation·C M AgressH J Swan
Dec 1, 1969·American Heart Journal·I Starr, R J Luchi
Jan 1, 1970·The Journal of Clinical Investigation·R KumarW H Abelmann
Oct 1, 1966·The Journal of Clinical Investigation·J W CovellE H Sonnenblick
Jun 14, 1984·The New England Journal of Medicine·R J LefkowitzG L Stiles
Mar 1, 1983·Journal of Cardiovascular Pharmacology·L Dei CasO Visioli
Sep 1, 1984·Journal of Cardiovascular Pharmacology·J H RenC V Leier
Oct 3, 1980·European Journal of Pharmacology·J S KarlinerC Dollery
Jan 1, 1984·Annual Review of Pharmacology and Toxicology·A E FarahR P Schwarz
Aug 1, 1984·Journal of the American College of Cardiology·H Scholz
Jan 1, 1984·Circulation·C S LiangW B Hood
Dec 1, 1984·Circulation·M PackerM Yushak
Nov 1, 1983·The American Journal of Cardiology·C S MaskinT H LeJemtel
May 24, 1984·The New England Journal of Medicine·S I RajferL I Goldberg
May 1, 1983·The American Journal of Cardiology·M Gheorghiade, G A Beller
Aug 1, 1982·The American Journal of Medicine·J L FlegE G Lakatta
Jul 1, 1981·Circulation Research·C S LiangW B Hood
Jul 1, 1981·The American Journal of Cardiology·K T WeberA P Fishman
Dec 1, 1981·Circulation·A J MossC L Odoroff